Compare Recursion Pharmaceuticals Inc (RXRX) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs First Trust Cloud Computing ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $4.32 (market cap $2.14B), while First Trust Cloud Computing ETF trades at $174.78 (market cap $3.47B). The key difference: First Trust Cloud Computing ETF is the larger of the two by market cap, and First Trust Cloud Computing ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and First Trust Cloud Computing ETF for 85 Days on average.
| RXRX | SKYY | |
|---|---|---|
Market Cap | $2.14B | $3.47B |
Volume | 30,789,535 | 176,159 |
Sector | Health | — |
52-Week High | $6.79 | $171.01 |
52-Week Low | $2.84 | $104.16 |
Typical Hold Time | 23 Days | 85 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
First Trust Cloud Computing ETF (SKYY) trades at $174.09, up 1.94% with bullish technical signals from moving averages. The ETF recently hit a new 52-week high, reflecting strong momentum in cloud computing stocks driven by AI infrastructure demand. Technical indicators show support at $169 and resistance at $171-173, with the current price near recent highs.
SKYY offers diversified exposure to cloud infrastructure and software companies benefiting from secular trends in AI adoption and digital transformation. Key risks include sector concentration and market volatility, while institutional sentiment remains positive given the long-term growth prospects in cloud computing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
